BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30805927)

  • 1. Role of the novel gene BZW2 in the development of hepatocellular carcinoma.
    Jin X; Liao M; Zhang L; Yang M; Zhao J
    J Cell Physiol; 2019 Sep; 234(9):16592-16600. PubMed ID: 30805927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BZW2/5MP1 acts as a promising target in hepatocellular carcinoma.
    Li G; Lu A; Chen A; Geng S; Xu Y; Chen X; Yang J
    J Cancer; 2021; 12(17):5125-5135. PubMed ID: 34335929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.
    Cheng DD; Li SJ; Zhu B; Yuan T; Yang QC; Fan CY
    Oncol Rep; 2017 Oct; 38(4):2116-2122. PubMed ID: 28791373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway.
    Huang L; Chen S; Fan H; Ai F; Sheng W
    J Cell Physiol; 2020 May; 235(5):4834-4842. PubMed ID: 31643092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic and Immune Significance of BZW2 in Pan-Cancer and its Relationship with Proliferation and Apoptosis of Cervical Cancer.
    Li C; Li Q; Li L; Sun S; Lei X
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):97. PubMed ID: 38538258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
    Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
    World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: A microarray pathway analysis.
    Gao H; Yu G; Zhang X; Yu S; Sun Y; Li Y
    J Cell Mol Med; 2019 Jun; 23(6):3905-3915. PubMed ID: 30932331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β.
    Jin K; Li Y; Wei R; Liu Y; Wang S; Tian H
    Cell Death Discov; 2024 Feb; 10(1):105. PubMed ID: 38424042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
    J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma.
    Ge J; Mu S; Xiao E; Tian G; Tao L; Li D
    Front Genet; 2022; 13():1002673. PubMed ID: 36267402
    [No Abstract]   [Full Text] [Related]  

  • 13. Promotion of BZW2 by LINC00174 through miR-4500 inhibition enhances proliferation and apoptosis evasion in laryngeal papilloma.
    Liu J; Yang T; Zhang Y; Wang S
    Cancer Cell Int; 2020; 20():471. PubMed ID: 33005104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3β Signaling Pathway in Human Hepatocellular Carcinoma.
    Zhou LJ; Mo YB; Bu X; Wang JJ; Bai J; Zhang JW; Cheng AB; Ma JH; Wang YW; Xie YX
    Cell Physiol Biochem; 2018; 50(3):851-867. PubMed ID: 30355923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box binding protein 1 augments sorafenib resistance
    Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
    World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA ADAMTS9-AS1 exacerbates cell proliferation, migration, and invasion via triggering of the PI3K/AKT/mTOR pathway in hepatocellular carcinoma cells.
    Zhang Z; Li H; Hu Y; Wang F
    Am J Transl Res; 2020; 12(9):5696-5707. PubMed ID: 33042449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells.
    Wei H; Hu J; Pu J; Tang Q; Li W; Ma R; Xu Z; Tan C; Yao T; Wu X; Long X; Wang J
    Int Immunopharmacol; 2019 Aug; 73():72-80. PubMed ID: 31082725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
    Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
    Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma.
    Huang G; Yang Y; Lv M; Huang T; Zhan X; Kang W; Hou J
    Onco Targets Ther; 2020; 13():9759-9770. PubMed ID: 33061455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.